Literature DB >> 39585

The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man.

S B Pearson, D C Banks, J M Patrick.   

Abstract

1 We have studied the effects of single oral doses of 80 mg propranolol and 100 mg metoprolol on the cardiovascular and respiratory responses to progressive exercise in nine healthy men in double-blind, placebo-controlled experiment. As judged by their effects on exercise heart rate and cardiac output the doses of the two drugs used were equivalent. 2 Beta-adrenoceptor blockade reduced oxygen consumption by 3.5% over the whole work range with an increase in the respiratory exchange ratio of 0.056 units. Carbon dioxide production and exercise ventilation were unchanged. The two drugs had similar effects. Possible mechanisms for these observations are discussed. 3 Perceived exertion during exercise was increased by both the beta-adrenoceptor blocking drugs and this may be of relevance to the symptom of fatigue reported by patients on these drugs. Endurance, assessed as either total work done or maximal work achieved, was reduced by 15%.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 39585      PMCID: PMC1429781          DOI: 10.1111/j.1365-2125.1979.tb05812.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  EFFECTS OF BETA-SYMPATHETIC BLOCKADE ON NON-ESTERIFIED-FATTY-ACID AND CARBOHYDRATE METABOLISM AT REST AND DURING EXERCISE.

Authors:  G G MUIR; D A CHAMBERLAIN; D T PEDOE
Journal:  Lancet       Date:  1964-10-31       Impact factor: 79.321

2.  CALORIGENIC EFFECT OF NOREPINEPHRINE CORRELATED WITH PLASMA FREE FATTY ACID TURNOVER AND OXIDATION.

Authors:  D STEINBERG; P J NESTEL; E R BUSKIRK; R H THOMPSON
Journal:  J Clin Invest       Date:  1964-02       Impact factor: 14.808

3.  Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro.

Authors:  L A CARLSON
Journal:  Acta Med Scand       Date:  1963-06

4.  STUDIES ON THE RELATION BETWEEN MOBILIZATION OF FREE FATTY ACIDS AND ENERGY METABOLISM IN MAN: EFFECTS OF NOREPINEPHRINE AND NICOTINIC ACID.

Authors:  R J HAVEL; L A CARLSON; L G EKELUND; A HOLMGREN
Journal:  Metabolism       Date:  1964-12       Impact factor: 8.694

5.  RELATIONSHIP BETWEEN FREE FATTY ACID TURNOVER AND TOTAL BODY OXYGEN CONSUMPTION IN THE EUTHYROID AND HYPERTHYROID STATES.

Authors:  R P EATON; D STEINBERG; R H THOMPSON
Journal:  J Clin Invest       Date:  1965-02       Impact factor: 14.808

6.  ON THE NERVOUS FACTORS CONTROLLING RESPIRATION AND CIRCULATION DURING EXERCISE. EXPERIMENTS WITH CURARIZATION.

Authors:  E ASMUSSEN; S H JOHANSEN; M JORGENSEN; M NIELSEN
Journal:  Acta Physiol Scand       Date:  1965-03

7.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

Authors:  P J RANDLE; P B GARLAND; C N HALES; E A NEWSHOLME
Journal:  Lancet       Date:  1963-04-13       Impact factor: 79.321

8.  The effect of exercise on the level of non-esterified fatty acids in the blood.

Authors:  A BASU; R PASSMORE; J A STRONG
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1960-07

9.  An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris.

Authors:  M B Comerford; E M Besterman
Journal:  Postgrad Med J       Date:  1976-08       Impact factor: 2.401

10.  Differential inhibition of lipolysis in human adipose tissue by adrenergic beta receptor blocking drugs.

Authors:  M Frisk-Holmberg; J Ostman
Journal:  J Pharmacol Exp Ther       Date:  1977-03       Impact factor: 4.030

View more
  34 in total

1.  Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

Authors:  R V Lewis; L E Ramsay; P R Jackson; W W Yeo; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

2.  Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina.

Authors:  S Wieshammer; M Hetzel; U Barnikel; M Höher; H Seibold; M Kochs; V Hombach
Journal:  Klin Wochenschr       Date:  1991-09-16

3.  Effect of partial agonist activity on the side effects of beta-blockade in patients with chronic stable angina.

Authors:  J Chambers; M L Ong; F Akhras; G Adam; G Jackson
Journal:  Drugs       Date:  1989       Impact factor: 9.546

4.  Ramp work tests with three different beta-blockers in normal human subjects.

Authors:  R L Hughson
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

5.  Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise.

Authors:  L Gullestad; L O Dolva; S E Kjeldsen; I Eide; J Kjekshus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

6.  Alterations in the oxygen deficit-oxygen debt relationships with beta-adrenergic receptor blockade in man.

Authors:  R L Hughson
Journal:  J Physiol       Date:  1984-04       Impact factor: 5.182

7.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.

Authors:  R G Wilcox; J R Hampton
Journal:  Br Heart J       Date:  1981-11

9.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

10.  A 31P-n.m.r. study of the acute effects of beta-blockade on the bioenergetics of skeletal muscle during contraction.

Authors:  R A Challiss; D J Hayes; G K Radda
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.